<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209556</url>
  </required_header>
  <id_info>
    <org_study_id>C2501003</org_study_id>
    <secondary_id>2019-003999-39</secondary_id>
    <nct_id>NCT04209556</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis</brief_title>
  <official_title>A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY WITH AN OPEN LABEL EXTENSION TO EVALUATE THE SAFETY AND EFFICACY OF PF-06826647 IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of PF-06826647 in moderate to
      severe ulcerative colitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">October 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 26, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants achieving endoscopic response</measure>
    <time_frame>At Week 8</time_frame>
    <description>Endoscopic response is defined by Mayo endoscopic index &lt; 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs), Serious Adverse Events (SAEs) based on severity and withdrawals due to adverse events (AEs)</measure>
    <time_frame>At Week 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>At Week 60</time_frame>
    <description>Following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with clinically significant changes in Electrocardiogram (ECG)</measure>
    <time_frame>At Week 60</time_frame>
    <description>Clinical significant changes in ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Categorical changes from baseline in Vital Signs Data</measure>
    <time_frame>At Week 60</time_frame>
    <description>Number of participants with increase from baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 60.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving clinical remission</measure>
    <time_frame>At Week 8 and 60</time_frame>
    <description>Clinical remission is defined by total Mayo score of ≤ 2 with no individual subscore of &gt; 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving endoscopic remission</measure>
    <time_frame>At Week 8 and 60</time_frame>
    <description>Endoscopic remission is defined as Mayo endoscopic index of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving mucosal healing</measure>
    <time_frame>At Week 8 and 60</time_frame>
    <description>Mucosal healing is defined as both total Mayo score and histologic index of ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving clinical response</measure>
    <time_frame>At Week 8 and 60</time_frame>
    <description>Clinical response is defined as a decrease from baseline of at least 3 points in total Mayo score with at least 30% change, accompanied by at least one point decrease or absolute score of 0 or 1 in rectal bleeding subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in partial Mayo score over time</measure>
    <time_frame>Up to 60 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total Mayo score</measure>
    <time_frame>At Week 8 and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs), Serious Adverse Events (SAEs) based on severity and withdrawals due to adverse events (AEs)</measure>
    <time_frame>At Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Laboratory Abnormalities</measure>
    <time_frame>At Week 8</time_frame>
    <description>Following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick [urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin], microscopy [urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous [urine mucus and leucocytes]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant changes in Electrocardiogram (ECG)</measure>
    <time_frame>At Week 8</time_frame>
    <description>Clinically significant changes from baseline in ECG (heart rate, QT, QTc, PR and QRS intervals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorical Vital Signs Data</measure>
    <time_frame>At Week 8</time_frame>
    <description>Number of participants with increase from baseline in sitting SBP and DBP of greater than or equal to 30 mmHg at Week 8.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06826647 100 mg once a day (QD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06826647 100 mg once a day (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06826647 300 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06826647 300 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06826647 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06826647 600 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Extension, PF-06826647 400 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06826647 400 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 100 mg QD</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>PF-06826647 100 mg once a day (QD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 300 mg QD</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>PF-06826647 300 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06826647 600 mg QD</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>PF-06826647 600 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-6826647 400 mg QD</intervention_name>
    <description>Investigational Product</description>
    <arm_group_label>Open Label Extension, PF-06826647 400 mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with moderate to severe UC as defined by a total Mayo score of ≥6, with a
             rectal bleeding subscore of ≥1 and an endoscopic subscore of ≥2;

          -  Participants must have inadequate response to, loss of response to, or intolerance to
             at least one conventional therapy for UC: Oral, intravascular, or intramuscular
             corticosteroids; Immunosuppressants (azathioprine [AZA], 6-MP, or methotrexate [MTX]);
             Anti-tumor necrosis factor (TNF) inhibitors (eg, infliximab, adalimumab, or
             golimumab); Anti-integrin inhibitors (eg, vedolizumab); JAK inhibitor (eg,
             tofacitinib); Anti-IL-12/IL-23 inhibitors (eg, ustekinumab).

        Exclusion Criteria:

          -  Presence of indeterminate colitis, microscopic colitis, ischemic colitis, infectious
             colitis, radiation colitis, and diverticular disease associated with colitis, or
             Crohn's disease

          -  Participants displaying clinical signs of fulminant colitis or toxic megacolon;

          -  Participants with evidence of colonic dysplasia, adenomas or neoplasia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ADVA Clinical Research</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centinela Valley Endoscopy Center</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inglewood Imaging Center</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Surinder Saini, M.D., Inc.</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Renaissance Imaging Center (CT/Xray)</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Valley Endoscopy Center (Colonoscopy/Flexible sigmoidoscopy)</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saludmax Medical Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Clinical Research of Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants P.C.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates (c/o TrialSpark, Inc.)</name>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <zip>46410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of New Jersey, LLC (c/o TrialSpark, Inc.)</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Physicians Ambulatory Surgery Center, LLC, dba Physicians Endoscopy Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Digestive Diseases Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann SW Surgery Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Victorium Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Radiology Imaging Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sugar Lakes Family Practice, PA</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterolgy Associates of Northern Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Northern Virginia</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Verity Research, Inc.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fair Oaks Imaging Center- Reston Radiology Consultants</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associates in Gastroenterology (c/o TrialSpark, inc)</name>
      <address>
        <city>Woodbridge</city>
        <state>Virginia</state>
        <zip>22192</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C2501003</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

